Recent developments in the molecular characterization and treatment of XXXX .

@entity1 @entity4174 @entity390 @entity353 @entity5 @entity391 @entity11770 @entity11 @entity816 @entity1891 @entity1485 @entity2903 @entity5771 @entity463 @entity3271
Although many @entity1 with @entity3271 ( @entity3271 ) and @entity816 ( @entity816 ) benefit from a combination of surgery and adjuvant radiotherapy, most @entity1 eventually experience recurrence of their disease. Recent evidence has shown that @entity3271 are more chemosensitive than other @entity11 , including @entity816 or @entity463 multiforme. These initial findings have prompted further study of chemotherapy in treating @entity3271 and mixed @entity816 . Advances in molecular genetic analysis have led to improvements in predicting response to chemotherapy and prognosis for @entity3271 , @entity816 , and @entity816 . Pure @entity3271 are more chemosensitive than mixed @entity3271 . This difference is related to different proportions of 1p/19q loss of heterozygosity in these @entity5 . Therefore, genetic analysis is likely to be key in determining appropriate treatment. The most common first-line chemotherapy for @entity1 with @entity5771 is a @entity4174 , @entity11770 , and @entity1891 ( @entity1485 ) combination regimen. However, this regimen is associated with cumulative myelosuppression, @entity390 , @entity391 , and @entity353 . Therefore, other chemotherapy agents and regimens have been investigated. Perhaps the most promising is @entity2903 , a novel alkylating agent that freely crosses the blood-brain barrier. @entity2903 is approved in the United States for the treatment of recurrent @entity816 and in Europe for any recurrent high-grade @entity11 . Initial reports suggest that @entity2903 is effective in treating @entity3271 as first- and second-line chemotherapy. Unlike the @entity1485 regimen, @entity2903 is not associated with cumulative myelosuppression and is usually well tolerated. Further studies are needed to confirm the efficacy and safety profile of @entity2903 and to determine the optimal dose and schedule for treating @entity3271 .
